China's AIDS vaccine starts Phase I clinical trial

on the occasion of the 20th World AIDS Day, China's AIDS research has come up with upbeat news: DNA - Tiantan pox seedling compound AIDS vaccine in Beijing ConcordHospitalbegan the first group of volunteers vaccination, which marks China with a new method of developing AIDS vaccine into Phase I clinical trialsThe AIDS vaccine was jointly developed by the ChinaCenter for Disease
Control and Prevention and the Beijing Institute of Biological Products with the support of the National 863 Program and the EU Fifth Framework INCO ProjectThe vaccine includes two components of the DNA vaccine and the replication of the recombinant pox virus vaccine, which has China's independent intellectual property rights, said Yan Yiming, chief expert of AIDS at the Center for Disease
control and prevention in
ChinaThe vaccine was originally selected from 4 genes of the main HIV epidemic strain in ChinaThe vector of the vaccine selected the Temple of Heavenpox virus, the pox virus has been widely used in China's smallpox vaccine, its safety has been fully verified by hundreds of millions of people applications, with its development of recombinant AIDS vaccine has passed the china inspection and national safety evaluation center of strict identification, quality qualified, and the National FoodDrugAdministration approved, to carry out Phase I clinical trialsYin Yiming said, and the international epidemic of AIDS vaccine design concept and technology route is very different, this clinical trial is a copy of the pox virus vector, belongs to the live vaccineLive vaccines can be replicated and produce strong immunityAnimal experiments have shown that the vaccine can induce good body fluids and cellular immune response in mice and monkeys, and can have a protective effect on monkey infection with human/monkey immunodeficiency virusInternational AIDS vaccine research has been more than 20 years, although the cost of more than 100 clinical trials, but there is no effective vaccineWith the failure of non-replicated vector vaccine, the international AIDS vaccine community is changing from non-replicated vector to replication vectorChina's ongoing hiv vaccine clinical trials are at the forefront of this trend.(Liu)